PROTEOSTASIS THERAPEUTICS, INC. PTI Cash Flow

Proteostasis therapeutics, inc. (PTI)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15
Cash flows from operating activities:
Net loss
-54,585	-59,125	-64,169	-69,764	-65,224	-61,832	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-44,337	-37,232	-33,446	-29,725	-27,291	-25,040	0	0	0
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization
1,420	1,414	1,409	1,388	1,566	1,778	1,829	1,821	1,625	1,402	1,059	839	580	306	321	285	276	272	0	0	0
Premium on short-term investments
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Accretion of short-term investments
667	958	1,083	923	700	438	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-
Non-cash rent expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Prepaid rent expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	599	0	0	0
Stock-based compensation expense
3,129	3,352	3,539	3,434	3,413	3,526	3,434	3,453	3,393	2,965	2,788	2,353	1,983	1,805	1,556	1,239	342	472	0	0	0
Stock issued for consulting services
-	242	427	597	750	889	916	919	817	767	0	0	0	-	-	-	-	-	-	-	-
Change in fair value of derivative liability
-	-	-	-	-	-22	0	-15	-24	-66	-139	-73	-20	89	-459	-273	-508	-63	0	0	0
Change in fair value of preferred stock warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-82	-169	-112	-111	-10	0	0	0
Changes in operating assets and liabilities:
Accounts receivable
-	-	-	-	-	-	-	-	-	-668	634	590	574	-250	-776	-2,443	-2,150	-506	0	0	0
Prepaids and other current assets
-645	-1,077	3	928	1,152	1,104	92	-629	-1,766	-2,682	-550	1,640	2,916	3,871	0	0	0	-	-	-	-
Other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Other assets
-	-	106	60	64	-33	-35	-35	-35	-35	-40	-52	-64	-76	-84	-123	-138	-182	0	0	0
Accounts payable
-796	406	1,933	1,330	792	-204	-400	-480	-214	67	-165	-1,491	-1,841	-289	-421	-527	2,337	361	0	0	0
Accrued expenses
-1,595	1,402	-1,809	558	1,674	-242	2,237	66	736	1,481	2,028	3,088	2,843	2,350	1,998	1,098	-929	498	0	0	0
Deferred revenue
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-4,675	-5,385	-2,313	-1,778	186	2,681	0	0	0
Operating lease liabilities
-1,079	-1,056	-1,033	-665	-1,328	-1,269	-1,350	-1,776	-1,171	-1,294	0	0	0	-	-	-	-	-	-	-	-
Net cash used in operating activities
-53,343	-53,222	-60,895	-65,030	-60,239	-58,844	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from investing activities:
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-48,873	-41,925	-34,345	-28,040	-23,282	-19,415	0	0	0
Purchases of short-term investments
72,896	88,508	143,676	129,527	124,127	111,240	68,097	67,373	57,784	61,220	0	0	0	-	-	-	-	-	-	-	-
Proceeds received from maturities of short-term investments
123,582	134,582	129,017	112,000	95,000	66,850	66,508	60,258	68,521	83,221	0	0	0	-	-	-	-	-	-	-	-
Purchases of property and equipment
-	9	0	0	0	-	-	-	-	118	314	303	215	229	62	276	280	263	0	0	0
Net cash provided by investing activities
50,686	46,065	-14,677	-17,545	-29,551	-44,805	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from financing activities:
Proceeds from issuance of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	46,500	0	0	0	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-54,857	-67,028	-56,348	-263	-280	-263	0	0	0
Proceeds from exercise of stock options
-	3	3	3	3	21	22	28	48	31	154	249	231	268	166	81	97	95	0	0	0
Proceeds from issuance of common stock pursuant to employee stock purchase plan
51	78	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of short-term borrowings
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of short-term borrowings
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs
-	-	-	-	-	431	0	0	0	-	-	-	-	-	-	0	0	-	-	-	-
Net cash provided by financing activities
4,424	3,355	91,164	91,281	101,623	101,613	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash, cash equivalents and restricted cash
1,767	-3,802	15,592	8,706	11,833	-2,036	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	69,342	113,722	113,602	69,073	69,074	24,729	0	0	0
Net decrease in cash, cash equivalents, and restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	4,769	22,909	40,770	45,512	5,051	0	0	0
Supplemental disclosure of non-cash investing and financing activities:
Conversion of convertible preferred stock into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	112,292	0	0	0	-	-	-	-
Issuance of common stock to settle accrued Series A preferred stock dividends
-	-	-	-	-	-	-	-	-	-	-	-	-	3	0	0	0	-	-	-	-
Issuance of common stock for partial payment of accrued bonus
-	-	-	-	-	-	-	-	-	-	-	-	-	62	0	0	0	-	-	-	-
Capital expenditures incurred but not yet paid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Conversion of preferred stock warrants into common stock warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Deferred offering costs included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,288	0	0	0
Employee Stock Purchase Plan [Member]
Proceeds from issuance of common stock
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Addition of Operating Lease Right-Of-Use Asset [Member]
Capital expenditures incurred but not yet paid
-	-	-	-	-	14,962	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-